

Final Agenda
40th meeting of the Committee for Risk Assessment

6– 10 March 2017
and
14 – 15 March 2017

ECHA Conference Centre (Annankatu 18, Helsinki)

Monday 6 March starts at 14.00
Friday 10 March breaks at 13.30
Tuesday 14 March resumes at 9.00
Wednesday 15 March ends at 13.30

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

RAC/A/40/2017
For adoption

Item 3 – Declarations of conflicts of interest to the Agenda

For information

Item 4 – Report from other ECHA bodies and activities

- a) Report on RAC 39 action points, written procedures and update on other ECHA bodies

RAC/40/2017/01

RAC/40/2017/02

Room document

For information

- b) RAC workplan for all processes

For information

Item 5 – Requests under Article 77 (3)(c)

No requests.

Item 6 – Requests under Article 95 (3)

- a) OEL-DNEL methodology

RAC/40/2017/03
For agreement

Item 7 – Harmonised classification and labelling (CLH)

7.1 General CLH issues

7.2 CLH dossiers

A. Hazard classes for agreement without plenary debate (fast-track)

Mandestrobin (ISO): no classification for the following hazards: physical hazards, acute toxicity (all routes of exposure), STOT SE, skin /eye irritation, skin sensitisation, STOT RE, germ cell mutagenicity

Methylmercuric chloride: Acute Tox. 2 (H330), Acute Tox. 2 (H300), STOT RE 1 (H372) (central nervous system, kidneys)

Pentapotassium 2,2',2'',2''',2''''-(ethane-1,2-diylnitrilo)pentaacetate (DTPA-K5): Acute Tox. 4 (H332)

Pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate (DTPA-Na5): Acute Tox. 4 (H332)

N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid) (DTPA-H5): Acute Tox. 4 (H332)

Thiabendazole (ISO) : Aquatic Acute 1 (H400), M=1. Aquatic Chronic 1 (H410), M=1

For agreement/adoption

B. Hazard classes for agreement with plenary debate

- a) Glyphosate (ISO)
b) 2-Benzyl-2-dimethylamino-4'-morpholinobutyrophenone
c) Mandestrobin (ISO)
d) Methylmercuric chloride
e) pentapotassium 2,2',2'',2''',2''''-(ethane-1,2-diylnitrilo)pentaacetate (DTPA-K5)
f) N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid) (DTPA-H5)
g) Pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate (DTPA-Na5)

For discussion and adoption

C. Dossiers for key issues debate

- h) Titanium dioxide

For discussion only

7.3 Appointment of RAC (co-)rapporteurs for CLH dossiers

RAC/40/2017/04

Restricted room document

For agreement

Item 8 – Restrictions

8.1 Restriction Annex XV dossiers

a) Conformity

1. Diisocyanates – conformity and key issues discussion
2. Lead in PVC – conformity and key issues discussion

For agreement

b) Opinion development

1. TDFAs – third draft opinion
2. 4 phthalates- third draft opinion

For adoption

8.2 Appointment of (co-)rapporteurs for restriction dossiers

RAC/40/2017/05

Restricted document

For agreement

Item 9 – Authorisation

9.1 General authorisation issues

a) Updated working procedure for the authorisation process

RAC/40/2017/06

RAC/40/2017/07

b) New applications received during the February 2017 submission window

c) Report from the AfA Task Force

d) Feedback from seminar 'Man via the Environment'

For information

e) RAC Reference values

1. Carcinogenicity dose-response relationship development and DNEL setting for the reprotoxic properties for coal tar pitch high temperature (CTPHT)
2. Carcinogenicity dose-response relationship development for anthracene oil

For discussion

9.2 Authorisation applications

a) Discussion on key issues

1. SD_Colle (1 use)

2. CT_Hansgrohe (2 uses)
3. SD_Hapoc (1 use)

For discussion

- b) Agreement on draft opinions
1. CT_Reachlaw (4 uses)
 2. CT_Clariant (1 use)
 3. CT_Cryospace (1 use)
 4. SD_Borealis (1 use)
 5. SD_Ormezzano (2 uses)
 6. AD_BAE (2 uses)
 7. EDC_Biotech (1 use)
 8. EDC_ORGAPHARM (2 uses)
 9. EDC_Akzo (1 use)
 10. Diglyme_Roche (1 use)
 11. Diglyme_LifeTech (1 use)
 12. Diglyme_Acton (2 uses)

For discussion and agreement

- c) Discussion on draft opinions
1. MOCA_Reachlaw (1 use)
 2. CT_Haas (1 use)
 3. SD_Haas (1 use)
 4. PD_Haas (1 use)
 5. SC_Aviall (2 uses)
 6. CT_Hapoc (4 uses)
 7. CT_Hapoc_2 (1 use)
 8. CT_Hapoc_3 (1 use)

For discussion

- d) Adoption of final opinions
1. AsA_Circuit (1 use)
 2. CT Circuit (1 use)
 3. EDC_Eli Lilly (1 use)
 4. CT_Gerhardi (1 use)

For discussion and adoption

9.3 Appointment of (co-)rapporteurs for authorisation applications

RAC/40/2017/08

Restricted room document

For agreement

Item 10 – AOB

Item 11 – Action points and main conclusions of RAC-40

Table with Conclusions and Action points from RAC-40

For adoption